Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: Incremental benefit, debatable value

Journal of Clinical Oncology

Volumn 29, Issue 9, 2011, Pages 1095-1098

  West, Howard ^a  

^a SWEDISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; HUMANS; NEOPLASMS; RANK LIGAND; TREATMENT OUTCOME;

EID: 79952748286     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.5596     Document Type: Editorial

References (15)

1. Mundy GR: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593, 2002
2. Gralow JR, Bierman JS, Farooki A, et al: NCCN task force report: Bone health in cancer care. J Natl Compr Canc Netw 7:S1-S32, 2009 (suppl 3)
3. Saad F, Gleason DM, Murray R, et al: A randomized placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002
4. Rosen LS, Gordon D, Tchekmedyian S, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157, 2003 (Pubitemid 46606297)
5. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001 (Pubitemid 33759002)
6. Bekker PJ, Holloway DL, Rasmussen AS, et al: A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066, 2004 (Pubitemid 41110556)
7. Body JJ, Facon T, Coleman RE, et al: A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221-1228, 2006 (Pubitemid 43342512)
8. Lipton A, Steger GG, Figueroa J, et al: Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25:4431-4437, 2007 (Pubitemid 350013849)
9. Brown JE, Cook RJ, Major P, et al: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69, 2005
10. Coleman R, Brown J, Terpos E, et al: Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions. Cancer Treat Rev 34:629-639, 2008
11. Henry DH, Costa L, Goldwasser F, et al: Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125-1132, 2011
12. Stopeck AT, Lipton A, Body J-J, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 28:5132-5139, 2010
13. Fizazi K, Carducci MA, Smith MR, et al: A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 28:951s, 2010 (suppl; abstr LBA4507)
14. Hirsh V, Major PP, Lipton A, et al: Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 3:228-236, 2008 (Pubitemid 351654321)
15. Fizazi K, Lipton A, Mariette X, et al: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564-1571, 2009